Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,586 recalls · Class II, newest first

Class II · Moderate risk

Anastrozole Tablets

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Terminated Cross-contamination Zydus Pharmaceuticals USA Inc NDC 68382-209-10 D-1441-2019
Class II · Moderate risk

ANASTROZOLE Tablets

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Terminated Cross-contamination Zydus Pharmaceuticals USA Inc NDC 68382-209-06 D-1440-2019
Class II · Moderate risk

Senna (sennosides 8.8 mg)

Failed Impurities/Degradation Specifications: Atypical odor and unpleasant taste was reported

Terminated Impurity / degradation Geritrex, LLC NDC 54162-007-08 D-1437-2019
Class II · Moderate risk

Senna (sennosides 8.8 mg)

Failed Impurities/Degradation Specifications: Atypical odor and unpleasant taste was reported

Terminated Impurity / degradation Geritrex, LLC NDC 53807-556-08 D-1436-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer

Terminated Nitrosamine impurity Heritage Pharmaceuticals, Inc. NDC 23155-645-10 D-1287-2019
Class II · Moderate risk

Articaine DENTAL

Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine DENTAL is a trade name for Lidocaine HCL 2% and Epinephrine 1: 100,000 formulation, while Articadent DENTAL is a trade name for Articaine HCI 4% and Epinephrine 1 :100,000. The cartridges contained within the printed carton are labeled appropriately as Articadent DENTAL.

Terminated Labeling / mix-up Septodont Inc. NDC 66312-601-16 D-1307-2019

Recalls by year